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Abstract: Novel complexes of 1,2-P,N-bidentate ferrocenyl ligands with AgOAc or with [RuCl2(PPh3)3]
as catalysts have been studied in asymmetric synthesis. The catalytic activity of these systems have
been studied in [3+2]-cycloaddition of azomethine ylides with olefins and the asymmetric transfer
hydrogenation of ketones.
Keywords: ferrocenyl ligands; catalysis; cycloaddition; hydrogen transfer
1. Introduction
Planar chiral 1,2-bidentate ferrocenyl ligands, as well as binaphthyls, bi(hetero)aryls,
and spirobiindans, are widely spread in versatile reactions of asymmetric synthesis reactions [1].
They are connected with the ability, at low concentrations, of the catalyst to provide a high degree of
enantioselectivity and high yield of target products. Such ligands are essential for the production of
pharmaceuticals and natural products.
To date, a variety of complexes from the available chiral ligands, including ferrocenes,
with transition metals have been developed for asymmetric cycloaddition reactions. For example, CuI or
AgI/TF-BiphamPhos (ee up to 99%, C. -J. Wang) [2–5], CuI/Fesulphos (ee up to 96%, J. C. Carretero) [6,7],
AgI/xylyl-FAP (ee up to 97%, X. Zhang) [8], CuI/Ming-Phos (ee up to 95%, J. Zhang) [9], AgI/QUINAP
(ee up to 96%, S. L. Schreber) [10], AgI/FPOX (ee up to 98%, Y. -G. Zhou) [11–13] and AgI/BINAP (ee
up to 99%, J. M. Sansano) [14–17]. Ferrocene-based catalysts were successfully applied in the asymmetric
[3+2]-cycloaddition of azomethine ylides with olefins as well [18–27]. Moreover, the use of ferrocenyl chiral
complexes in small amounts, such as Rh/JoSPOphos [28], Ru/Josiphos [29], and ReV/(R,S)-Josiphos [30],
in enantioselective hydrogenation of carbonyl compounds, is significant for chemistry.
In our previous work, an efficient and straightforward route for the synthesis of planar chiral
(hetaryl)ferrocenes P,N-ligands L1 (er > 99:1) and L2 (er > 99:1) (Figure 1) has been demonstrated [31].
The obtained (hetaryl)ferrocenes revealed high catalytic activity in the Pd-catalyzed Tsuji–Trost allylic
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substitution [31]. In the present paper, the catalytic activity of chiral complexes based on the ligands
L1 and L2 in the [3+2]-cycloaddition of azomethine ylides with olefins and the asymmetric transfer
hydrogenation of ketones is demonstrated.
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2. Results and Discussion
Asymmetric [3+2]-cycloaddition [32] represents one of the most efficient, straightforward,
and atom-economi al methods for the constructi n of optically active pyrrolidine derivatives with
multiple ster ocenters. Aft r pioneeri g studies of asymmetric pyrrolidines s nthesis [8,33],
many efforts were directed to the development of synthetic approaches to novel chiral catalysts.
Chiral pyrrolidines are present in many biologically active [34–36] and natural [37] compounds,
and were recently often applied as organocatalysts [38–44]. For instance compound 1 demonstrates
an antiviral activity against hepatitis C (as an inhibitor of RNA polymerase) [45,46], and α-kainic
acid (2) has a neuroexcitatory effect [47]. (–)-Dysibetaine (3) is a neuroexcitotoxin which may bind to
the glutamate receptors presented in the CNS of mice [48]. Hydroxyprolines 4 and 5 play an important
role in the cataboli m of collagen, and i the st bilization of rot collagens and glycoproteins in
living systems [49]. Derivatives of pyrrolopyrans 6 [23] are known to be the analogues of natural
monoterpenoids of the class of cyclopentanopyranes (iridoids), performing protective functions in the
organism. Lactam 7 is thrombin inhibitor (Figure 2) [50].
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Given the importance of the pyrrolidine scaffold, we studied asymmetric [3+2]-cycloaddition using
the developed chiral ligands. Initially, the cycloaddition of methyl (E)-2-((4-bromobenzylidene)imino)
acetate (8a) to N-methylmaleimide (9a) was selected as a model reaction for testing the activity of new
ligands, such as (SFc)-[2-(2-quinolin-2-yl)-ferrocen-1-yl]-diphenylphosphine (L1) and (RFc)-1-(quinolin-2-yl)-
2-(α-(R)-diphenylphosphinoethyl)ferrocene (L2). The reaction was carried out in the presence of
substoichiometric amounts of triethylamine and tetrakis(acetonitrile)copper(I) tetrafluoroborate (5 mol %)
at room temperature. Product 10a was obtained in 65% yield and er = 50:50 in absence of chiral ligand
(Table 1, entry 1). Applying complex L1 with tetrakis(acetonitrile)copper(I) tetrafluoroborate, product 10a
was obtained with an er = 76:24 and 45% yield (Table 1, entry 2). Afterwards, we tried to increase the
yield and the selectivity of the reaction by employing various Lewis acids, such as AgF and AgOAc
with L1 (Table 1, entries 3 and 4) [2–4,15,16,51,52]. The reaction with L1/AgF resulted in 58% yield of
product 10a and er = 50:50. Using AgOAc with ligand (L1), the target product was formed with er = 85:15
and 50% yield. Complex L1 with AgOAc was prepared in situ by stirring for 15 min at room temperature
in dichloromethane. There was a change in the color of the reaction mixture from orange to dark red after
the formation of the complex. The structure of complex L1/AgOAc was confirmed by nuclear magnetic
resonance (NMR) spectroscopy, high-resolution mass spectrometry (HRMS), and elemental analysis (see
Supplementary Materials page S2, S19, figures S2, S4, S20, S22). The signals of the protons of the ferrocene
and heterocyclic moieties of the complex L1/AgOAc (3.9–5.4 and 7.4–7.9 ppm) are downfield shifted by
0.1–0.3 ppm and 0.1–0.2 ppm compared to those of the initial L1 ligand (3.8–5.1 and 7.2–8.0 ppm). In the 31P
spectra of the complex, a downfield shift by 5.9 ppm relative to the free ligand was also observed.
Table 1. Asymmetric [3+2]-cycloaddition of methyl (E)-2-((4-bromobenzylidene)imino)acetate 8a and
N-methylmaleimide 9a.
Molecules 2018, 23, x FOR PEER REVIEW  3 of 12 
 
Given the importance of the pyrrolidine scaffold, we studied asymmetric [3+2]-cycloaddition using 
the developed chiral ligands. Initially, the cycloaddition of methyl (E)-2-((4-bromobenzylidene) 
imino)acetate (8a) to N-methylmaleimide (9a) was selected as a model reaction for testing the activity 
of new ligands, such as (SFc)-[2-(2-quinolin-2-yl)-ferrocen-1-yl]-diphenylphosphine (L1) and 
(RFc)-1-(quinolin-2-yl)-2-(α-(R)-diphenylphosphinoethyl)ferrocene (L2). The reaction was carried out 
in the presence of substoichiometric amounts of triethylamine and tetrakis(acetonitrile)copper(I) 
tetrafluoroborate (5 mol %) at room temperature. Product 10a was obtained in 65% yield and  
er = 50:50 in absence of chiral ligand (Table 1, entry 1). Applying complex L1 with 
tetrakis(acetonitrile)copper(I) tetrafluoroborate, product 10a was obtained with an er = 76:24 and 
45% yield (Table 1, entry 2). Afterwards, we tried to increase the yield and the selectivity of the 
reaction by employing various Lewis acids, such as AgF and AgOAc with L1 (Table 1, entries 3 and 
4) [2–4,15,16,51,52]. The reaction with L1/AgF resulted in 58% yield of product 10a and er = 50:50. 
Using AgOAc with ligand (L1), the target product was formed with er = 85:15 and 50% yield. 
Complex L1 with AgOAc was prepared in situ by stirring for 15 min at room temperature in 
dichloromethane. There was a change in the color of the reaction mixture from orange to dark red 
after the formation of the complex. The structure of complex L1/AgOAc was confirmed by nuclear 
magnetic resonance (NMR) spectroscopy, high-resolution mass spectrometry (HRMS), and 
elemental analysis (see Supplementary Materials page S2, S19, figures S2, S4, S20, S22). The signals 
of the protons of the ferrocene and heterocyclic moieties of the complex L1/AgOAc (3.9–5.4 and 7.4–
7.9 ppm) are downfield shifted by 0.1–0.3 ppm and 0.1–0.2 ppm compared to those of the initial L1 
ligand (3.8–5.1 and 7.2–8.0 ppm). In the 31P spectra of the complex, a downfield shift by 5.9 ppm 
relative to the free ligand was also observed. 
Table 1. Asymmetric [3+2]-cycloaddition of methyl (E)-2-((4-bromobenzylidene)imino)acetate 8a 
and N-methylmaleimide 9a. 
 
Entry Ligand [M]/Base Yield (%) 
10а  
er (%) 
10a 
1 - [Cu(CH3CN)4][BF4]/Et3N 65 50:50 
2 L1 [Cu(CH3CN)4][BF4]/Et3N 45 76:24 
3 L1 AgF/Et3N 50 50:50 
4 L1 AgOAc/Et3N 50 85:15 
Based on the above results, we concluded that the optimal conditions for this transformation 
are as follows: dichloromethane, 5 mol % AgOAc, 6 mol % ligand, and room temperature. In order to 
investigate the effect of the substituent on the yield and selectivity of the products, imino  
esters 8 with donor and acceptor substituents in the benzene ring were synthesized [23,53]. The 
cycloaddition of methyl (E)-2-((4-bromobenzylidene)imino)acetate (8a) and methyl 
(E)-2-((4-chlorobenzylidene)imino)acetate (8b) with N-methylmaleimide (9a) led to the formation of 
products 10a and 10b in 50% and 69% yields, respectively (Scheme 1). A similar reaction of 8a and 8b 
with N-phenylmaleimide (9b) proceeded with the formation of products 10d and 10e in 64% and 
34% yields and 98:2 and 93:7 er, respectively (Scheme 1). The attempt to employ methyl 
(E)-2-((4-methoxybenzylidene)imino)acetate failed. Product 10c was obtained in 45% yield and er = 
63:37 using N-methylmaleimide as a dipolarophile, and its structural analogue 10f was obtained in 
60% yield and er = 70:30 using N-phenylmaleimide. 
Entry Ligand [M]/Base Yield (%)10a
er (%)
10a
1 - [Cu(CH3CN)4][BF4]/Et3N 65 50:50
2 L1 [Cu(CH3CN)4][BF4]/Et3N 45 76:24
3 L1 AgF/Et3N 50 50:50
4 L1 AgOAc/Et3N 50 85:15
Based on the above results, we concluded that the optimal conditions for this transformation are
as follows: dichloromethane, 5 mol % AgOAc, 6 mol % ligand, and roo te perature. In order to
investigate the effect of the substituent on the yield and selectivity of the products, imino esters 8 with
donor and acceptor substituents in the benzene ring were synthesized [23,53]. The cycloaddition of methyl
(E)-2-((4-bromobenzylidene)imino)acetate (8a) and methyl (E)-2-((4-chlorobenzylidene)imino)acetate (8b)
with N-methylmaleimide (9a) led to the formation of products 10a and 10b in 50% and 69% yields,
respectively (Scheme 1). A similar reaction of 8a and 8b with N-phenyl aleimide (9b) proceeded
ith the formation of products 10d and 10e in 64% and 34% yields and 98:2 and 93:7 er, respectively
(Scheme 1). The attempt to employ methyl (E)-2-((4-methoxybenzylidene)imino)acetate failed. Product 10c
was obtained in 45% yield and er = 63:37 using N-methylmaleimide as a dipolarophile, and its structural
analogue 10f was obtained in 60% yield and er = 70:30 using N-phenylmaleimide.
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and N-alkylmaleimide (9) catalyzed by the complex L1/AgOAc: a The enantiomeric ratio was determined
by high-performance liquid chromatography (HPLC) on Chiralpak AD. b The enantiomeric ratio was
determined by HPLC on a Chiralcel OD-H. c The enantiomeric ratio was determined by supercritical fluid
chromatography (SFC) on a Chiralcel OD-H. d Use of the L2/AgOAc complex.
Notably, using (RFc)-1-(quinolin-2-yl)-2-(α-(R)-diphenylphosphinoethyl)ferrocene L2, the product 10d
was obtained in 55% yield as a racemate (er = 50:50) using the optimized reaction conditions (Scheme 1).
A plausible mechanism is shown in Scheme 2. In the first step of the reaction, silver(I) is simultaneously
coordinated by the bidentate chiral ligand L1 and the substrate 8 in a tetrahedral arrangement to
form the catalytic complex A. Next step of deprotonation of complex A by triethylamine leads to the
formation of the azomethine ylide, the active substrate for the cycloaddition. This active substrate then
undergoes a cycloaddition with dienophile 9 to furnish the product 10a (Scheme 2). The dienophile attacks
from the less-hindered side (above the plane), to avoid unfavorable steric interactions with the bulky
diphenylphosphine group of the ligand [20].
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The structures of the cycloaddition products 10a–f have been confirmed by NMR spectroscopy,
and the data corresponding well with the literature [53,54]. In addition, we carried out nuclear
Overhauser effect spectroscopy (NOESY) experiments for compound 10a, to gain structural and
stereochemical information. The NOESY experiment showed a NOE effect of the H-3 to H-3a, and H-1
to H-6a, enabling the determination of the stereochemistry of this compound as endo-product (Figure 3).
Absolute configuration was determined by comparison with the literature data [54]. The enantiomeric
ratio of the compounds was determined by high-performance liquid chromatography (HPLC) and
supercritical fluid chromatography (SFC) analysis.
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The asymmetric hydrogenation of double bonds is known to be of great importance in the
synthesis of biologically active compounds and their precursors. For example, (S)-Duloxetine (11) is
an antidepressant drug targeting the presynaptic cell and (R)-Fluoxetine (12) is an antidepressant of
the selective serotonin reuptake inhibitor (SSRI) class (Figure 4) [55–57]. In particular, ferrocenyl chiral
complexes [29,30,58,59] are utilized for the carbonyl group reduction.
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Next, we tried to examine the catalytic activity of pla ar chiral ferrocenyl ligands L1 and L2
applying the Ru-catalyzed transfer hydrogenation of ketones with acetophenone 13 as a model
substrate (Scheme 3, Table 2).
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(3.9–5.4 and 7.4–7.9 ppm) in comparison to the initial ligand L1 (3.8–5.1 and 7.2–8.0 ppm) are downfield
shifted by 0.1–0.3 ppm and 0.1–0.2 ppm, respectively. It should be noted that in the 31P spectra of the
complex, the signal is downfield shifted by 5.6 ppm relative to the initial ligand.
Asymmetric transfer hydrogenation of acetophenone 13 to (R)-1-phenylethanol 14 was carried
out in the presence of 0.5 mol % of complex L1/RuCl2(PPh3)3 and 2 mol % t-BuOK. The reaction
mixture was stirred under argon atmosphere for 20 h at room temperature. (R)-1-phenylethanol 14
was isolated by column chromatography on SiO2 in 20% yield and with the selectivity of more than
99% (Table 2, entry 2). The asymmetric transfer hydrogenation conditions were optimized with respect
to the type and amount of base and the reaction temperature (Table 2).
The application of 4-dimethylaminopyridine (DMAP) and NaH as bases provided low yields
of product 14 (Table 2, entries 3 and 4). Furthermore, 14 was obtained in 2% yield after 72 h in the
presence of 20 mol % using triethylamine as base (Table 2, entry 5). Next, we tried to increase the yield
by heating to 80 ◦C (Table 2, entry 6). At last, (R)-1-phenylethanol 14 in 98% yield was achieved by
carrying out the reaction at 80 ◦C in the presence of 20 mol % t-BuOK (Table 2, entry 7). Reducing
the loading of t-BuOK to 10 and 2 mol % resulted in a slight decrease in the product yield (Table 2,
entries 8 and 9). The selectivity of the process in all above cases with L1/RuCl2(PPh3)3 was more
than 99%.
Table 2. Transfer hydrogenation of acetophenone 15 under different reaction conditions.
Entry Ligand T (◦C) Base(mol %) Time (h)
Yield (%)
14
er (%) 1
14
1 - RT t-BuOK (2) 48 30 2 1:1
2 L1 RT t-BuOK (2) 48 20 2 >99:1
3 L1 RT DMAP (2) 48 - -
4 L1 RT NaH (2) 48 11 3 >99:1
5 L1 RT Et3N (20) 72 2 3 >99:1
6 L1 80 Et3N (20) 20 40 3 >99:1
7 L1 80 t-BuOK (20) 20 98 3 >99:1
8 L1 80 t-BuOK (10) 20 97 3 >99:1
9 L1 80 t-BuOK (2) 20 96 3 >99:1
10 L2 80 t-BuOK (20) 20 53 3 >99:1
1 The enantiomeric ratio was determined by SFC on a Lux Amylose-2. 2 The product was isolated by column
chromatography on SiO2. 3 The yield was determined by NMR spectroscopy.
In the reaction with L2/RuCl2(PPh3)3 complex, the selectivity of (R)-1-phenylethanol (14) was
also more than 99% with a yield of 53% (Table 2, entry 10).
Based on the above results, we conclude that the optimal conditions for this transformation are as
follows: 20 mol % t-BuOK, 0.5 mol % ligand, 0.5 mol % RuCl2(PPh3)3 and 80 ◦C. In order to investigate
the effect of the substituent on the yield and selectivity of the products, other ketones were used
(Scheme 4). The asymmetric transfer hydrogenation of 2-butanone 13b led to the formation of products
14b in 50% yields. Next, we investigated the ability of using of asymmetric transfer hydrogenation
for pi-excess and pi-deficient carbonyl compounds such as 2-acetylthiophene 13c and 2-acetylpyridine
13d (Scheme 4). (R)-1-(Thiophen-2-yl)ethan-1-ol 14c was isolated in trace amounts. This is interpreted
by the instability of thiophene derivatives. As opposed to 2-acetylthiophene, the asymmetric transfer
hydrogenation of pi-deficient 2-acetylpyridine 13d led to the formation of products 14d in high yield
and selectivity (Scheme 4).
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3. Materials and Methods
3.1. General Information
All reactions were carried out under argon using standard Schlenk Techniques (Hofmann
Glastechnik GmbH, Staudt, Germany). The 1H-NMR (400 MHz), 13C-NMR (100 MHz), 31P-NMR
(162 MHz) spectra were recorded on a NMR spectrometer (400 MHz). Chemical shifts are given in δ
values (ppm) using tetramethylsilane (TMS) as internal standard and CDCl3 as solvent. Electrospray
mass spectra were recorded in positive mode with maXis impact high resolution Q-TOF mass
spectrometer (Bruker Daltonics, Bremen, Germany) in 50–2500 Da mass range by direct infusion of
sample solutions in methanol using kdScientific (KD Scientific Inc., Holliston, MA, USA) syringe pump
at 120 µL/h flow rate. Modified instrument settings of a pre-installed method Direct_Infusion_100–1000
were used. Mass calibration was performed using ES-TOF G1969-85000 tuning mix (Agilent
Technologies) by HPC method (High Precision Calibration standard procedure by Bruker). All data
were collected and analyzed with Compass for oTof series 1.7/DataAnalysis 4.2 software package
(Bruker, Germany). Analytical HPLC (Knauer, Berlin, Germany) and SFC (Waters Corporation, Milford,
MA, USA) were performed using a chiral column. The angle of rotation was measured on a polarimeter
Perkin-Elmer 343+ (PerkinElmer Instruments, Llantrisant, Wales, UK). The elemental analysis was
carried out on a CHNS/O analyzer Perkin-Elmer (PerkinElmer Instruments, Norwalk, CT, USA).
The course of the reactions was monitored by thin layer chromatography (TLC) on silica gel plates
(Macherey-Nagel GmbH & Co, Düren, Germany). The column chromatography was performed on
silica gel (silica gel 60, 0.035−0.070 mm, 220−440 mesh).
Glycine methyl ester hydrochloride, N-methylmaleimide, N-phenylmaleimide, benzaldehydes,
acetophenone, Cu(CH3CN)4BF4, AgF, AgOAc, and [RuCl2(PPh3)3] were purchased from Aldrich
(Merck KGaA, Darmstadt, Germany). (SFc)-[2-(2-quinolin-2-yl)-ferrocen-1-yl]-diphenylphosphine (L1),
(RFc)-1-(quinolin-2-yl)-2-(α-(R)- diphenyl-phosphinoethyl)ferrocene (L2) [31] and imine 8 [23] were
prepared according to the published procedures.
. . e eral roce re for t e t esis of ro cts
i ( ol %) and AgOAc (5 mol %) w re dissolved in dichloromethane (1.0 mL) and
the solution was stirred for 15 min at room temperature. Then, dipolarophile 9 (1.2 mol), imine 8
(1 mol) and Et3N (20 mol %) w re a ded to the mixture and stirred at room te perature for 24 .
fter e r ti er re ce ress re, t e resi e s rifie t r c l c r t r
silic el ( exa e et l cet te 1) to give the pure r cts. e str ct res f r cts ere
[ ,54] and confirmed by NMR. The enantiomeric excesses of the products were determined by
HPLC and SFC on chiral stationary phase.
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Methyl (1R,3S,3aR,6aS)-3-(4-bromophenyl)-5-methyl-4,6-dioxooctahydropyrrolo[3,4-c]pyrrole-1-carboxylate
(10a) [54]. Obtained from imine 8a and N-methylmaleimide 9a, 0.183 g, 50%, white solid; [α]D20 =
+2.7 (c 0.16, CDCl3); HPLC: Chiralpak AD, λ = 220 nm, hexane/iPrOH/MeOH, 50:20:5, 0.6 mL/min,
retention time (tR): 20.5 min and 27.8 min.
Methyl (1R,3S,3aR,6aS)-3-(4-chlorophenyl)-5-methyl-4,6-dioxooctahydropyrrolo[3,4-c]pyrrole-1-carboxylate
(10b) [54]. Obtained from imine 8b and N-methylmaleimide 9a, 0.222 g, 69%, gray solid; [α]D20 =
+2.4 (c 0.15, CDCl3); HPLC: Chiralpak AD, λ = 220 nm, hexane/iPrOH/MeOH, 50:25:5, 1 mL/min,
tR: 10.45 min and 14.22 min.
Methyl(1R,3S,3aR,6aS)-3-(4-methoxyphenyl)-5-methyl-4,6-dioxooctahydropyrrolo[3,4-c]pyrrole-1-carboxylate
(10c) [54]. Obtained from imine 8b and N-methylmaleimide 9a, 0.143 g, 45%, dark beige solid; [α]D20 =
−0.7 (c 0.12, CDCl3); HPLC: Chiralpak AD, λ = 220 nm, hexane/iPrOH/MeOH, 50:25:5, 1 mL/min,
tR: 13.87 min and 17.42 min.
Methyl (1R,3S,3aR,6aS)-3-(4-bromophenyl)-4,6-dioxo-5-phenyloctahydropyrrolo[3,4-c]pyrrole-1-carboxylate
(10d) [53]. Obtained from imine 8a and N-phenylmaleimide 9b, 0.274 g, 64%, light gray solid; [α]D20 =
+61.3 (c 0.15, CDCl3); SFC: Chiralcel OD-H, λ = 220 nm, CO2/MeOH, 75:25, 0.8 mL/min, 140 bar,
tR: 15.74 min and 24.67 min).
Methyl (1R,3S,3aR,6aS)-3-(4-chlorophenyl)-4,6-dioxo-5-phenyloctahydropyrrolo[3,4-c]pyrrole-1-carboxylate
(10e) [53]. Obtained from imine 8b and N-phenylmaleimide 9b, 0.130 g, 34%, dark gray solid; [α]D20 =
+3.4 (c 0.1, CDCl3); HPLC: Chiralcel OD-H, λ = 220 nm, hexane/iPrOH/MeOH, 50:20:5, 1 mL/min,
tR: 21.80 min and 28.18 min).
Methyl(1R,3S,3aR,6aS)-3-(4-methoxyphenyl)-4,6-dioxo-5-phenyloctahydropyrrolo[3,4-c]pyrrole-1-carboxylate
(10f) [53]. Obtained from imine 8c and N-phenylmaleimide 9b, 0.228 g, 60%, beige solid; [α]D20 =
−0.2 (c 0.14, CDCl3); SFC: Chiralcel OD-H, λ = 220 nm, CO2/MeOH, 75:25, 0.8 mL/min, 140 bar,
tR: 15.57 min and 22.28 min.
3.3. General Procedure for the Synthesis of Products 14
A solution of ketone (1 mmol) and a base (20 mol %) was added to a solution of complex
L1/RuCl2(PPh3)3 (0.5 mol %) in degassed iPrOH (30 mL). The reaction mixture was stirred at 80 ◦C
for 20 h, and the progress of the reaction was monitored by TLC. After evaporation under reduced
pressure, the residue was purified through column chromatography on silica gel to yield pure product.
The structures of products were known and were confirmed by NMR spectroscopy.
(R)-1-Phenylethanol (14a) [30]. Obtained from acetophenone 13a, 0.120 mg, 98%, yellow oil; [α]D20 = +1.3
(c 0.06, CDCl3); SFC: Lux Amylose-2, λ = 210 nm, CO2/MeOH, 98:2, 1 mL/min, 140 bar, tR: 6.1 min.
(R)-2-Butanol (14b) [60]. Obtained from 2-butanone 13b, 0.037 g, 50%; SFC: Lux Amylose-2, λ = 275 nm,
CO2/MeOH, 95:5, 0.8 mL/min, 140 bar, tR: 5.1 min.
(R)-1-(Pyridin-2-yl)ethanol (14d) [61]. Obtained from 2-acetylpyridine 13d, 0.102 g, 83%; SFC: Chiralcel
OD-H, λ = 266 nm, CO2/MeOH, 90:10, 1 mL/min, 140 bar, tR: 2.4 min.
4. Conclusions
New Ag- and Ru-catalysts based on the planar chiral ferrocene P,N-ligands L1 and L2
have been obtained. The scope of activity of the complexes was demonstrated in two types of
asymmetric reactions: [3+2]-cycloaddition of azomethine ylides with olefins and asymmetric transfer
hydrogenation of carbonyl compounds. The catalytic activity of the ligands L1 and L2 has been shown
to be comparable with the ones of previously described ligands in the presented transformations.
Thus, the obtained complexes revealed high reactivity and good enantioselectivity and enabled to
access to optically active pyrrolidine derivatives and products of reduction of multiple bonds under
Molecules 2018, 23, 1311 9 of 12
mild conditions. As the final step, we succeeded to apply the approach to the synthesis of potential
biologically active compounds.
Supplementary Materials: The following are available online. The Supporting Materials contains copies of all
1H-, 13C- and 31P-NMR spectra, HPLC, SFC, HRMS and elemental analysis data.
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